canada clinical guidance

Vulvovaginal candidiasis (thrush)

A Canadian clinical summary of vulvovaginal candidiasis (thrush), with source-attributed priorities and explicit jurisdiction boundaries.

JurisdictionCanada
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals practising in Canada
This is an iatroX educational summary of named Canada sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.

Source and scope

This summary is bounded to the recommendations, population and decisions covered by Vulvovaginitis: Screening for and Management of Trichomoniasis, Vulvovaginal Candidiasis, and Bacterial Vaginosis. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:SOGC vulvovaginitis

Source-attributed clinical priorities

  • Confirm typical vulvovaginal symptoms and signs and reconsider bacterial vaginosis, STI, dermatitis and vulvar disease when atypical.
  • Use topical or oral azole treatment according to pregnancy, severity, recurrence, interactions and patient preference.
  • Culture or arrange specialist assessment for recurrent, complicated or nonresponsive disease rather than repeating empiric therapy indefinitely.
  • Recurrent or complicated symptoms should be confirmed microbiologically before repeated antifungal treatment.
sources for this section:SOGC vulvovaginitis

Practical assessment and management workflow

1
Assess itch, soreness, discharge, dysuria, pregnancy, diabetes, antibiotics and immune status.
2
Examine vulva and vagina and use microscopy or culture for atypical, recurrent or resistant disease.
3
Choose topical or oral treatment by severity, pregnancy, species likelihood and interaction risk.
4
Review recurrence for glycemic control, dermatitis, resistant species and alternative diagnoses.
sources for this section:SOGC vulvovaginitis

Safety, red flags and urgent escalation

  • Avoid oral fluconazole in pregnancy unless specialist guidance supports a specific circumstance.
  • Ulceration, pelvic pain, fever or systemic symptoms are not typical uncomplicated candidiasis.
  • Check major drug interactions and liver risk before prolonged oral azole therapy.
sources for this section:SOGC vulvovaginitis

Confirm the local pathway before acting

The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:SOGC vulvovaginitis

Source and implementation boundary

Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:SOGC vulvovaginitis

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Society of Obstetricians and Gynaecologists of CanadaVulvovaginitis: Screening for and Management of Trichomoniasis, Vulvovaginal Candidiasis, and Bacterial Vaginosisaccessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Found a source update or regional discrepancy? Tell the iatroX editorial team.